BRPI0520588A2 - composições farmacêuticas para o tratamento de distúrbios do ouvido interno - Google Patents

composições farmacêuticas para o tratamento de distúrbios do ouvido interno

Info

Publication number
BRPI0520588A2
BRPI0520588A2 BRPI0520588-3A BRPI0520588A BRPI0520588A2 BR PI0520588 A2 BRPI0520588 A2 BR PI0520588A2 BR PI0520588 A BRPI0520588 A BR PI0520588A BR PI0520588 A2 BRPI0520588 A2 BR PI0520588A2
Authority
BR
Brazil
Prior art keywords
treatment
pharmaceutical compositions
inner ear
compositions
ear disorders
Prior art date
Application number
BRPI0520588-3A
Other languages
English (en)
Inventor
Thomas Meyer
Original Assignee
Auris Medical Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37019770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0520588(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auris Medical Ag filed Critical Auris Medical Ag
Publication of BRPI0520588A2 publication Critical patent/BRPI0520588A2/pt
Publication of BRPI0520588B1 publication Critical patent/BRPI0520588B1/pt
Publication of BRPI0520588B8 publication Critical patent/BRPI0520588B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Acoustics & Sound (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçõES FARMACêUTICAS PARA O TRATAMENTO DE DISTúRBIOS DO OUVIDO INTERNO. A presente invenção refere-se a composições contendo (1) um agente farmaceuticamente ativo selecionado de um grupo consistindo em uma arilcicloalquilamina ou um derivado, análogo ou sal farmaceuticamente ativo da mesma e (ii) um polímero biocompatível ou uma combinação de polímeros biocompatíveis. Essas composições ou medicamentos contendo essas composições podem ser usados para a prevenção e/ou tratamento de doenças do ouvido interno, por exemplo, tinido.
BRPI0520588A 2005-09-28 2005-09-28 uso de composições farmacêuticas para o tratamento de doenças do ouvido interno BRPI0520588B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/010478 WO2007038949A1 (en) 2005-09-28 2005-09-28 Pharmaceutical compositions for the treatment of inner ear disorders

Publications (3)

Publication Number Publication Date
BRPI0520588A2 true BRPI0520588A2 (pt) 2009-05-19
BRPI0520588B1 BRPI0520588B1 (pt) 2018-07-10
BRPI0520588B8 BRPI0520588B8 (pt) 2021-05-25

Family

ID=37019770

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520588A BRPI0520588B8 (pt) 2005-09-28 2005-09-28 uso de composições farmacêuticas para o tratamento de doenças do ouvido interno

Country Status (25)

Country Link
US (5) US20090246255A1 (pt)
EP (2) EP2792347A1 (pt)
JP (1) JP2009509982A (pt)
KR (1) KR101271263B1 (pt)
CN (1) CN101309667A (pt)
AU (1) AU2005337107B2 (pt)
BR (1) BRPI0520588B8 (pt)
CA (1) CA2620374C (pt)
CU (1) CU20080044A7 (pt)
CY (1) CY1115891T1 (pt)
DK (1) DK1928405T3 (pt)
EA (1) EA017264B1 (pt)
ES (1) ES2524994T3 (pt)
HR (1) HRP20140920T1 (pt)
IL (1) IL189622A (pt)
ME (1) ME01956B (pt)
NO (1) NO339356B1 (pt)
NZ (1) NZ566062A (pt)
PL (1) PL1928405T3 (pt)
PT (1) PT1928405E (pt)
RS (1) RS53591B1 (pt)
SI (1) SI1928405T1 (pt)
TN (1) TNSN08079A1 (pt)
WO (1) WO2007038949A1 (pt)
ZA (1) ZA200802762B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060205789A1 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Gacyclidine formulations
EA017264B1 (ru) 2005-09-28 2012-11-30 Аурис Медикаль Аг Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US20090088844A1 (en) 2007-07-03 2009-04-02 Keegan Mark E Drug-eluting stapes prosthesis
AU2016228201A1 (en) * 2008-04-21 2016-10-13 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
KR101449785B1 (ko) * 2008-04-21 2014-10-14 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
BRPI0912482A2 (pt) 2008-05-14 2020-08-18 Otonomy, Inc composições de corticosteróide de liberação controlada e métodos para o tratamento de distúrbios auriculares
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
GB2461962B (en) * 2008-07-25 2011-02-16 Otonomy Inc Slow release NMDA receptor antagonist for otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
RU2493828C2 (ru) * 2008-07-14 2013-09-27 Отономи, Инк. Модулирующие апоптоз композиции с контролируемым высвобождением и способы лечения заболеваний уха
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CA2731769C (en) * 2008-07-21 2013-09-10 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
MX2011000862A (es) * 2008-07-21 2011-03-15 Otonomy Inc Composiciones antimicrobianas de liberacion controlada y metodos para el tratamiento de trastornos oticos.
US9173864B2 (en) 2008-10-22 2015-11-03 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
WO2010074992A2 (en) * 2008-12-22 2010-07-01 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
EP2409683A1 (en) 2010-07-06 2012-01-25 KRKA, D.D., Novo Mesto Stable aqueous formulations comprising poorly water soluble active ingredients
US9073819B2 (en) 2011-06-30 2015-07-07 University Of South Florida Compositions, methods of use, and methods of treatment
US10130514B2 (en) * 2011-09-26 2018-11-20 Incube Labs, Llc System and method for delivery of a therapeutic agent to the inner ear
JP5941159B2 (ja) 2011-12-12 2016-06-29 オトラーヌム アーゲー 聴覚系における塩素イオン共輸送体ｎｋｃｃ１の調節による耳鳴の治療
BR112015007647A2 (pt) 2012-10-08 2017-07-04 Auckland Uniservices Ltd derivados de quetamina
US20140348787A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Methods and Compositions for Treating Ear Infections
JP2016534121A (ja) 2013-08-27 2016-11-04 オトノミ—，インク． 小児の耳の病気の処置
EP3964203A1 (en) 2013-09-13 2022-03-09 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
WO2015051259A1 (en) * 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
EP3984525A1 (en) * 2014-06-12 2022-04-20 Adare Pharmaceuticals USA, Inc. Extended-release drug delivery compositions
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. OTIC GEL FORMULATIONS FOR THE TREATMENT OF EXTERNAL OTITIS
MX2020007479A (es) * 2018-01-10 2020-11-24 Xwpharma Ltd Profármacos de ketamina, composiciones y usos de los mismos.
JP7492917B2 (ja) 2018-02-09 2024-05-30 デシベル セラピューティクス インコーポレイテッド 抗白金化学保護剤を含む高張医薬組成物
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
EP3761970A4 (en) * 2018-03-26 2022-06-08 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
CN112533595A (zh) 2018-05-04 2021-03-19 感知神经科学公司 治疗物质滥用的方法
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
US20200214976A1 (en) * 2019-01-09 2020-07-09 Spiral Therapeutics, Inc. Self-gelling solutions for administration of therapeutics to the inner ear
EP4199917B1 (en) 2020-08-18 2026-01-07 Oakwood Laboratories, LLC Microsphere formulations comprising ketamine and methods for making and using the same
WO2022112511A1 (en) * 2020-11-26 2022-06-02 Alain Moussy Pharmaceutical composition for treatment of inner ear disorders through local administration in the tympanic area
WO2022140636A1 (en) * 2020-12-22 2022-06-30 Otonomy, Inc. Gacyclidine otic formulations and uses thereof
TWI781536B (zh) 2021-02-26 2022-10-21 國立臺灣科技大學 藥物釋放組合物、其製造方法及其用途
US11753378B2 (en) 2021-04-19 2023-09-12 Zevra Therapeutics, Inc. Ketamine compounds and processes for making and using them
CN117881394A (zh) 2021-08-13 2024-04-12 凯瑞康宁生物工程（武汉）有限公司 氯胺酮衍生物的药物组合物和口服剂型

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254124A (en) * 1962-06-29 1966-05-31 Parke Davis & Co Aminoketones and methods for their production
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
EP0772225B1 (en) * 1994-07-15 2003-03-19 Hitachi, Ltd. Electronic energy filter
WO1996009044A1 (en) * 1994-09-22 1996-03-28 Richard Alan Smith Compositions useful for the preparation of medicines for treating a variety of intractable disorders
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
DE19528388A1 (de) 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents
AU2676397A (en) 1996-04-18 1997-11-07 University Technology Corporation Methods for treating middle and inner ear disorders
WO1998010757A2 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
US6045528A (en) * 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US6309410B1 (en) * 1998-08-26 2001-10-30 Advanced Bionics Corporation Cochlear electrode with drug delivery channel and method of making same
DE19853299C2 (de) * 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
CA2373994A1 (en) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6017961A (en) * 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
DE19936719A1 (de) 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte 1,5-Dihydropyrrol-2-on-Derivate
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
JP2001187737A (ja) * 1999-10-18 2001-07-10 Toyama Chem Co Ltd 聴力改善剤
AU2001257295A1 (en) 2000-05-01 2001-11-12 Georgetown University In vivo assay for identifying nucleic acid sequences involved in alveolar loss, development and nucleic acid sequences identified thereby
DE10025238A1 (de) * 2000-05-22 2001-11-29 Gruenenthal Gmbh Verwendung substituierter 1-Amino-5-phenylpentan-3-ol- und/oder 1-Amino-6-phenylhexan-3-ol- Verbindungen als Arzneimittel
BRPI0002693B8 (pt) 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
DE10044649A1 (de) * 2000-09-08 2002-07-04 Gruenenthal Gmbh Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
DE10124953A1 (de) 2001-05-21 2002-12-12 Marlies Knipper Substanz für die therapeutische Behandlung von Tinnitus
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030143195A1 (en) * 2002-01-30 2003-07-31 Pinsker Judy Senior Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery
US6638081B2 (en) * 2002-03-22 2003-10-28 Hon Hai Precision Ind. Co., Ltd. Electrical connector
US20040037311A1 (en) 2002-08-07 2004-02-26 Phonex Broadband Corporation Digital narrow band power line communication system
CA2497867A1 (en) 2002-09-06 2004-03-18 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
US6969383B2 (en) * 2002-09-27 2005-11-29 Medtronic, Inc. Method for treating severe tinnitus
ATE457299T1 (de) * 2002-11-12 2010-02-15 Gruenenthal Gmbh 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
EP1438942A1 (en) 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
CN100581621C (zh) 2003-05-16 2010-01-20 拉瓦勒大学 Cns氯化物调节及其用途
EP1699431B1 (en) 2003-12-12 2015-08-19 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
EA017264B1 (ru) 2005-09-28 2012-11-30 Аурис Медикаль Аг Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха

Also Published As

Publication number Publication date
SI1928405T1 (sl) 2014-12-31
EP1928405A1 (en) 2008-06-11
ZA200802762B (en) 2015-11-25
NZ566062A (en) 2009-08-28
CN101309667A (zh) 2008-11-19
ES2524994T3 (es) 2014-12-16
US20150196569A1 (en) 2015-07-16
HRP20140920T1 (hr) 2014-12-05
US20140364836A1 (en) 2014-12-11
JP2009509982A (ja) 2009-03-12
IL189622A (en) 2016-10-31
KR20080074093A (ko) 2008-08-12
US20150265532A1 (en) 2015-09-24
NO339356B1 (no) 2016-12-05
AU2005337107B2 (en) 2012-05-24
WO2007038949A1 (en) 2007-04-12
BRPI0520588B8 (pt) 2021-05-25
IL189622A0 (en) 2008-06-05
PL1928405T3 (pl) 2015-03-31
DK1928405T3 (da) 2014-12-15
EA200800798A1 (ru) 2008-10-30
CU20080044A7 (es) 2011-04-26
NO20081919L (no) 2008-04-22
EA017264B1 (ru) 2012-11-30
EP2792347A1 (en) 2014-10-22
EP1928405B1 (en) 2014-09-24
CY1115891T1 (el) 2017-01-25
PT1928405E (pt) 2014-10-20
CA2620374C (en) 2012-12-11
KR101271263B1 (ko) 2013-06-07
AU2005337107A1 (en) 2007-04-12
US9066865B2 (en) 2015-06-30
ME01956B (me) 2015-05-20
BRPI0520588B1 (pt) 2018-07-10
CA2620374A1 (en) 2007-04-12
US20150250719A1 (en) 2015-09-10
TNSN08079A1 (en) 2009-07-14
RS53591B1 (sr) 2015-02-27
US20090246255A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
BRPI0520588A2 (pt) composições farmacêuticas para o tratamento de distúrbios do ouvido interno
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
EP1848270A4 (en) TRANSMUCOSAL ADMINISTRATION OF MEDICINAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF DISEASES IN ANIMALS
NO20071512L (no) Terapeutiske kombinasjoner omfattende poly(ADP-ribose)polymeraseinhibitor.
WO2007070677A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
BR0306858A (pt) Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma
HUS1900037I1 (hu) Orális mikrobaellenes gyógyszerészeti kompozíciók
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
BR0115531A (pt) Tratamento de mucosites
BRPI0509863A (pt) liberação de fármaco para fundo de olho
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
DE60121301D1 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
CN104159635B (zh) 用于耳蜗内递送治疗剂以治疗耳部病症的固体药物植入物
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
FI3006038T3 (fi) Oritavansiinin yksittäisannokset bakteeri-infektion hoitoon tai ehkäisyyn
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
WO2010036052A3 (ko) 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 조성물
JP2019523229A (ja) 抗微生物化合物及びその使用方法
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BR0013793A (pt) Medicamentos profiláticos e terapêuticos para doenças oftálmicas
EA200800949A1 (ru) Способы лечения и профилактики среднего отита посредством химических веществ, способствующих проникновению, для обеспечения трансмембранного поступления лекарственного средства в среднее ухо
WO2007144080A3 (de) Antidepressiva-kombinations-wafer
TW200719903A (en) Compositions for the treatment of neoplasms

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AURIS MEDICAL AG (CH)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080146277/RJ DE 26/11/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2794 DE 23-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.